Depomed Sues Cadila, Zydus Over Generic Gralise

Law360, New York (May 11, 2012, 12:11 PM EDT) -- Drug company Depomed Inc. lodged a patent infringement suit Wednesday in New Jersey in an effort to block plans by Indian drugmaker Cadila Healthcare Ltd. and its U.S. subsidiary to market a generic version of epilepsy medication Gralise.

California-based Depomed brought suit after Cadila and Zydus Pharmaceuticals (USA) Inc. sought federal approval of an abbreviated new drug application to make and sell a generic version of Gralise before Depomed’s six patents had expired.

“Zydus has declared its intent to manufacture, use, offer to sell or sell...
To view the full article, register now.